Efficacy of Methotrexate in the treatment of plaque psoriasis in a local population
Keywords:
Methotrexate, Plaque psoriasisAbstract
Objective Plaque psoriasis constitutes around 90% prevalent in the world. Methotrexate has been widely used to treat psoriasis and associated arthritis. The objective of the study is to determine the efficacy of methotrexate in the treatment of plaque psoriasis. Methods The interventional descriptive single-arm pre and post-study was conducted in the department of dermatology FFH Rawalpindi from Aug 2018 to Jan 2021. 142 patients suffering from plaque type psoriasis with PASI score of >8 were included. Oral methotrexate in dose of 10 mg/week was given for 8 weeks to patients from dermatology. Results Mean pretreatment and post treatment PASI score shows drop from baseline (13.01±6.02) to eight weeks PT (5.4±3.2) which is statistically significant (P≤0.05). The change in percentage of PASI from baseline was analyzed by the Wilcoxon signed ranks test after 8 weeks (t=17.29) i.e. PASI 75 was achieved in more than 50% of participants. PA, that 26 out of 29 (96.29%) patients had moderate PA with DAS 28 score of less than 5 while 1(3.7%) patient had mild and 2(7.4%) had severe joint disease of greater than 5.1 DAS 28 score before methotrexate treatment. 17/29 (62.9%) achieved complete remission in joint disease after 8 weeks of methotrexate. Conclusion The outcome of this study has shown that the effective way to treat plaque psoriasis is through methotrexate.References
Global report on psoriasis [Internet]. Who. int. 2022 [cited 24 September 2022]. Available from: https://www.who.int/publications-detail-redirect/global-report-on-psoriasis
Schön M. Adaptive and Innate Immunity in Psoriasis and Other Inflammatory Disorders. Front Immunol. 2019;10:764.
Nestle F, Kaplan D, Barker J. Psoriasis. New Eng J Med. 2009;361(5):496-509.
Dogra S, Mahajan R. Psoriasis: Epidemiology, clinical features, co-morbidities, and clinical scoring. Indian Dermatol Online J. 2016;7(6):471.
Dogra S, Mahajan R. Psoriasis: Epidemiology, clinical features, co-morbidities, and clinical scoring. Indian Dermatol Online J. 2016;7(6):471.
Koca T. A summary of clinical types of psoriasis. Northern Clinics of Istanbul. 2016.
Drexler H. Burgdorf, Plewig, Wolff, Landthaler (eds): Braun-Falco’s dermatology. Int Arch Occup Environ Health. 2013;87(1):115.
Krueger J. Psoriasis pathophysiology: current concepts of pathogenesis. Ann Rheum Dis. 2005;64(suppl_2):ii30-ii36.
Coleman W. Fitzpatrick's Dermatology in General Medicine by Klaus Wolff, Lowell A. Goldsmith, Stephen I. Katz, Barbara A. Gilchrest, Amy S. Paller, and David J. Leffell, Editors. Dermatologic Surgery. 2008;34(8):1081-1081.
Henseler T, Christophers E. Psoriasis of early and late onset: Characterization of two types of psoriasis Vulgaris. J Am Acad Dermatol. 1985;13(3):450-6.
. Christophers E. Comorbidities in psoriasis. Clin Dermatol. 2007;25(6):529-34.
Nehring P, Przybyłkowski A. Is Psoriasis Treatment a Risk Factor for Inflammatory Bowel Disease? Pharmaceut Med. 2020;34(4):257-62.
Christophers E. Comorbidities in psoriasis. Clin Dermatol. 2007;25(6):529-34.
Global N, Porter M, Kimball A. 569 The patient perspective on psoriasis disease remission. J Invest Dermat. 2018;138(5): S97.
Boffa M, Chalmers R. Methotrexate for psoriasis. Clin Exp Dermatol. 1996;21(6):399-408.
Shen D, Azarnoff D. Clinical Pharmacokinetics of Methotrexate1. Clin Pharmacok. 1978;3(1):1-13.
Quake S, Lee M. e35 Is pre-methotrexate folate measurement helpful in predicting methotrexate side effects and methotrexate survival? Rheumatology. 2018;57(suppl_3).
Agustina M, Hidayati AN, Hasanatuludhhiyah N. Side Effects of Methotrexate for Psoriasis Therapy. BIKK. 2020;32(2):98-102.
van Huizen A, Sikkel R, Caron A, Menting S, Spuls P. Methotrexate dosing regimen for plaque-type psoriasis: an update of a systematic review. J Dermatol Treat. 2022;1-15.
Jones G, Crotty M, Brooks P. Interventions for treating psoriatic arthritis. Cochrane Database Syst Rev. 2000;2000(3): CD000212.
Goujon, C., Nicolas, J. and Nosbaum, A. Methotrexate in psoriasis. J Eur Acad Dermatol Venereol. 2019;33(4).
Roenigk HH Jr, Auerbach R, Maibach HI, Weinstein GD. Methotrexate in psoriasis: revised guidelines. J Am Acad Dermatol. 1988;19:145-56
Ortega-Alonso A, Andrade R. Chronic liver injury induced by drugs and toxins. J Digest Dis. 2018;19(9):514-21.
2. Conway R, Carey J. Risk of liver disease in methotrexate treated patients. World J Hepatol. 2017;9(26):1092.
Attiya Tareen, Hadia Y. Baseline Psoriasis Area and Severity Index, Disease Activity Score and Investigations for treatment with oral methotrexate in patients of Plaque Psoriasis. An Audit Report. www.unisonpublishers.com/wp-content/uploads/2022/07.
